{"id":"W3088871285","doi":"10.1016/j.annonc.2020.08.1147","title":"1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre; Université Laval; University of Alberta; Alberta Health Services; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Pembrolizumab; Pharmacodynamics; Discontinuation; Internal medicine; Pharmacology; Pharmacokinetics; Cancer; Chemotherapy; Phases of clinical research; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003770571,0.0002279648,0.0005608895,0.0002438754,0.0002345782,0.0005291912,0.0001777907,0.0003180714,0.003724447],"category_scores_gemma":[0.0004716803,0.0001522014,0.0004885717,0.0003011657,0.0001778966,0.0003692704,0.000168875,0.0005711028,0.0006815133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004095313,"about_ca_system_score_gemma":0.0005471407,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007143585,"about_ca_topic_score_gemma":0.002783595,"domain_scores_codex":[0.9998825,0.00003469892,0.00001194816,0.00002184776,0.00001588058,0.00003318967],"domain_scores_gemma":[0.9998457,0.00003214711,0.0000240802,0.00000833802,0.00001183348,0.00007789188],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3333448,0.00704434,0.1016286,0.001428729,0.002032203,0.001377995,0.0003428193,0.002528149,0.04526324,0.0006597928,0.01684005,0.4875093],"study_design_scores_gemma":[0.08555546,0.2428227,0.5832448,0.0005769334,0.003670646,0.005222658,0.000811616,0.006093898,0.01190671,0.001237208,0.05875044,0.0001069104],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877492,0.005349634,0.0001101313,0.000546932,0.0001596698,0.000127659,0.000730046,0.0000360771,0.00519077],"genre_scores_gemma":[0.9934124,0.00244528,0.0004014638,0.0003181785,0.000109807,0.00009432673,0.001059148,0.00000512037,0.002154264],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003724447,"threshold_uncertainty_score":0.01245952,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03444758884456375,"score_gpt":0.3272966723986475,"score_spread":0.2928490835540837,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}